



# Microglia are effector cells of CD47-SIRP $\alpha$ antiphagocytic axis disruption against glioblastoma

Gregor Hutter<sup>a,b,c,d,1</sup>, Johanna Theruvath<sup>a,b,c,1</sup>, Claus Moritz Graef<sup>a,b,c,1</sup>, Michael Zhang<sup>a</sup>, Matthew Kenneth Schoen<sup>a,b,c</sup>, Eva Maria Manz<sup>a,b,c</sup>, Mariko L. Bennett<sup>e</sup>, Andrew Olson<sup>f</sup>, Tej D. Azad<sup>a,b,c</sup>, Rahul Sinha<sup>b,c</sup>, Carmel Chan<sup>g</sup>, Suzana Assad Kahn<sup>a,b,c</sup>, Sharareh Gholamin<sup>a,b,c</sup>, Christy Wilson<sup>a</sup>, Gerald Grant<sup>a</sup>, Joy He<sup>a,b,c</sup>, Irving L. Weissman<sup>b,c,2</sup>, Siddhartha S. Mitra<sup>a,b,c,h,2,3,4</sup>, and Samuel H. Cheshier<sup>a,b,c,i,2,3,5</sup>

<sup>a</sup>Division of Pediatric Neurosurgery, Department of Neurosurgery, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA 94305; <sup>b</sup>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305; <sup>c</sup>Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford, Stanford University School of Medicine, Stanford, CA 94305; <sup>d</sup>Department of Neurosurgery, University Hospital Basel, CH-4031 Basel, Switzerland; <sup>e</sup>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305; <sup>f</sup>Neuroscience Microscopy Center, Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA 94305; <sup>g</sup>Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305; <sup>h</sup>Department of Pediatrics, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO 80045; and <sup>i</sup>Division of Pediatric Neurosurgery, Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112

Contributed by Irving L. Weissman, November 13, 2018 (sent for review December 18, 2017; reviewed by Frederic Geissmann and Jeremy N. Rich)

**Glioblastoma multiforme (GBM) is a highly aggressive malignant brain tumor with fatal outcome. Tumor-associated macrophages and microglia (TAMs) have been found to be major tumor-promoting immune cells in the tumor microenvironment. Hence, modulation and reeducation of tumor-associated macrophages and microglia in GBM is considered a promising antitumor strategy. Resident microglia and invading macrophages have been shown to have distinct origin and function. Whereas yolk sac-derived microglia reside in the brain, blood-derived monocytes invade the central nervous system only under pathological conditions like tumor formation. We recently showed that disruption of the SIRP $\alpha$ -CD47 signaling axis is efficacious against various brain tumors including GBM primarily by inducing tumor phagocytosis. However, most effects are attributed to macrophages recruited from the periphery but the role of the brain resident microglia is unknown. Here, we sought to utilize a model to distinguish resident microglia and peripheral macrophages within the GBM-TAM pool, using orthotopically xenografted, immunodeficient, and syngeneic mouse models with genetically color-coded macrophages (*Ccr2*<sup>RFP</sup>) and microglia (*Cx3cr1*<sup>GFP</sup>). We show that even in the absence of phagocytizing macrophages (*Ccr2*<sup>RFP/RFP</sup>), microglia are effector cells of tumor cell phagocytosis in response to anti-CD47 blockade. Additionally, macrophages and microglia show distinct morphological and transcriptional changes. Importantly, the transcriptional profile of microglia shows less of an inflammatory response which makes them a promising target for clinical applications.**

antiphagocytic (“don’t eat me”) surface protein CD47 which binds to its cognate receptor SIRP $\alpha$  on phagocytic cells inhibiting its phagocytic activity (8). CD47-SIRP $\alpha$  myeloid checkpoint blockade has been shown to effectively enhance tumor phagocytosis and

## Significance

**Tumor-associated microglia and macrophages (TAMs) constitute up to one half of the cells in glioblastoma multiforme (GBM) and are known to promote tumor growth. Therefore, modulation and reeducation of the TAM pool is a promising antitumor strategy against GBMs. We recently showed that disruption of the SIRP $\alpha$ -CD47 signaling axis is efficacious against various brain tumors including GBM primarily by inducing tumor phagocytosis. Here, we show that tumor-associated microglia are capable of in vivo tumor cell phagocytosis in response to anti-CD47 blockade. The activation of microglia was associated with distinct morphological and transcriptional changes. In fact, microglia show a dampened inflammatory response upon anti-CD47 therapy compared with macrophages, making them an attractive target for clinical applications especially in the confined regions of the brain.**

anti-CD47 | microglia | glioblastoma | immunotherapy | checkpoint inhibition

**G**lioblastoma multiforme (GBM, World Health Organization grade IV) is a fatal brain tumor resistant to all conventional treatment (1). A significant proportion of the tumor mass is made up of nonneoplastic cells which play a major role in tumor growth and progression. Recent studies show complex interactions between tumor cells and the microenvironment, highlighting the crucial role of nonneoplastic cells for therapy response (2). The pool of tumor-associated macrophages (TAMs) accounts for the majority of nonneoplastic cells including peripheral macrophages from hematopoietic stem cells (HSCs) and brain-resident microglia which originate from immature yolk sac progenitors (3, 4). In the tumor environment TAMs have immune suppressive functions. The fact that as many as 30–50% of the cells in gliomas are microglia and macrophages raises the intriguing potential of reeducating tumor-associated microglia (TA-MG) and macrophages (TA-MAC) to act as antitumor effector cells (5). Numerous studies have demonstrated the distinct roles of microglia and macrophages in CNS diseases (6, 7). A well-characterized mechanism of immune evasion by tumor cells is the up-regulation of the

Author contributions: G.H., J.T., I.L.W., S.S.M., and S.H.C. designed research; G.H., J.T., C.M.G., M.Z., M.K.S., E.M.M., A.O., T.D.A., R.S., C.C., S.A.K., S.G., C.W., J.H., and S.S.M. performed research; G.H., J.T., C.M.G., M.L.B., A.O., C.W., G.G., and S.S.M. contributed new reagents/analytic tools; G.H., J.T., C.M.G., M.Z., M.L.B., A.O., S.A.K., I.L.W., S.S.M., and S.H.C. analyzed data; and G.H., J.T., C.M.G., I.L.W., S.S.M., and S.H.C. wrote the paper.

Reviewers: F.G., Memorial Sloan Kettering Cancer Center; and J.N.R., University of California San Diego Medical Center.

Conflict of interest statement: S.G., S.S.M., S.H.C., and I.L.W. are coinventors on patents regarding the use of CD47 antibody targeting brain tumors. I.L.W. is the inventor of multiple patents regarding CD47 antibody targeting non-CNS tumors that have been licensed to Forty Seven, Inc. He serves on the board of directors and as a consultant. He has equity ownership in Forty Seven, Inc.

This open access article is distributed under [Creative Commons Attribution License 4.0 \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).

Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. [SRP158756](https://www.ncbi.nlm.nih.gov/nuclot/SRP158756)).

<sup>1</sup>G.H., J.T., and C.M.G. contributed equally to this work.

<sup>2</sup>To whom correspondence may be addressed. Email: [irv@stanford.edu](mailto:irv@stanford.edu), [siddhartha.mitra@ucdenver.edu](mailto:siddhartha.mitra@ucdenver.edu), or [samuel.cheshier@hsc.utah.edu](mailto:samuel.cheshier@hsc.utah.edu).

<sup>3</sup>S.S.M. and S.H.C. contributed equally to this work.

<sup>4</sup>Present address: Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.

<sup>5</sup>Present address: Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1721434116/-DCSupplemental](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1721434116/-DCSupplemental).

Published online January 2, 2019.

hence reduce tumor burden (9, 10). However, most effects are attributed to macrophages recruited from the periphery, but the role of the brain resident microglia is unknown (10). Genetic lineage tracing experiments revealed that expression of the chemokine receptor CCR2 is restricted to inflammatory monocytes and macrophages, whereas the fractalkine receptor CX3CR1 is highly expressed by microglia from early development (11). In consequence, *Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> reporter mice have been used to differentiate between macrophages and microglia (6). Here, we created a genetically color-coded mouse xenograft model (*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup>) on a NOD.Cg-Prkdc<sup>scid</sup>.Il2rgtm1<sup>Wjl/SzJ</sup> background, which allowed us to decipher the differential contribution of microglia and macrophages to the GBM-TAM pool at baseline and their response to the myeloid checkpoint inhibitor, anti-CD47. We found microglia capable of tumor cell phagocytosis, even in the absence of phagocytizing macrophages. Additionally, microglia show distinct morphological and transcriptional changes with a less inflammatory response. CD47 blockade can effectively reeducate microglia in the GBM tumor microenvironment to unleash the therapeutic potential of tumor cell phagocytosis.

## Results

**NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> Mice Were Generated and Validated to Distinguish Between Macrophages and Microglia in a Human GBM Xenograft Model.** To distinguish TA-MG from TA-MAC within the tumor environment, we created a genetically color-coded mouse xenograft model (*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup>) on a NOD.Cg-Prkdc<sup>scid</sup>.Il2rgtm1<sup>Wjl/SzJ</sup> background (SI Appendix, Fig. S1 A–C). These mice lack B, T, and natural killer (NK) cells but retain functioning macrophages and microglia. To determine if our NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> mouse model allows for a robust distinction between TA-MG and TA-MAC, we validated our model by RNA-sequencing as previous reports suggest a tumor-dependent transcriptional regulation of microglia- and macrophage-specific markers (12). NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice were orthotopically engrafted with T387 glioma cells expressing EBFP2-luciferase, and tumor engraftment was confirmed by bioluminescence imaging. After 25 d of tumor growth, TA-MG (defined as GFP<sup>high</sup>RFP<sup>negative</sup>) and TA-MAC (defined as GFP<sup>low</sup>RFP<sup>high</sup>) were sorted from dissociated xenografts by flow cytometry and processed for transcriptome analysis by RNA-seq (gating scheme: SI Appendix, Fig. S3). Principal component analysis and the heatmap of sample-to-sample distances showed distinct clusters for microglia and macrophages (SI Appendix, Fig. S2 A and B). Specifically, TA-MG were enriched for microglia-specific genes such as *Tmem119*, *Sall1*, and *Pros1* compared with TA-MAC (SI Appendix, Fig. S2C). TA-MAC, on the other hand, expressed significantly higher levels of *Iga4* and *Iga1* which have recently been reported to be robust markers for glioma-associated macrophages (SI Appendix, Fig. S2C) (12). *Ccr2* loss has been shown to prevent CNS infiltration by macrophages (13). Hence, we used *Ccr2* knockout mice (NSG-*Ccr2*<sup>RFP/RFP</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice) to investigate the role of TA-MG in absence of TA-MAC.

**The Microglial Composition of T387 Human GBM Xenografts Does Not Change in Response to Anti-CD47.** Utilizing this model, we investigated the tumor microenvironment and its response to myeloid checkpoint inhibition by using the humanized anti-CD47 monoclonal antibody Hu5F9-G4 (14). NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice were orthotopically engrafted with T387 glioma cells expressing EBFP2-luciferase. After confirming tumor engraftment by bioluminescence imaging, we started treatment with anti-CD47 (250 μg Hu5F9-G4 three times a week) or human IgG control and analyzed the tumor environment after 25 d by flow cytometry. The GBM-TAM composition in NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice was predominantly populated by microglia (GFP<sup>high</sup>RFP<sup>negative</sup>) (+367%,  $P < 0.0001$ ) compared with macrophages (GFP<sup>low</sup>RFP<sup>high</sup>) (Fig. 1A and B). Anti-CD47 led to significant influx of macrophages (+68%,  $P = 0.018$ ) but not microglia [not significant (n.s.)] (Fig. 1A Left and B).

We recapitulated the experiment in *Ccr2* knockout mice to elucidate whether there was an increase of microglia in the absence of infiltrating peripheral macrophages upon anti-CD47 treatment. No significant changes were observed in microglial composition (Fig. 1A and C). Even though *Ccr2* loss is known to prevent CNS infiltration by macrophages we observed a minor remaining GFP<sup>low</sup>RFP<sup>high</sup> population (Fig. 1A and C).

**Anti-CD47 Treatment Induces Microglial Tumor Phagocytosis in a GBM Xenograft Model.** To ascertain if TA-MG can act as effector cells upon CD47-SIRPα blockade, we analyzed the frequency of in vivo phagocytized tumor cells 3 wk after anti-CD47 or control treatment by flow cytometry. Indeed, anti-CD47 treatment induced a significant increase of in vivo tumor cell phagocytosis by TA-MG (2.7% control versus 13.3% treated,  $P < 0.0001$ ) as assessed by the presence of GFP<sup>high</sup>RFP<sup>negative</sup>EBFP2<sup>+</sup> microglia (Fig. 2A and C). We also observed enhancement of tumor cell phagocytosis by TA-MAC (1.7% control versus 5.2% treated,  $P = 0.0003$ ) defined by RFP<sup>high</sup>GFP<sup>low</sup>EBFP2<sup>+</sup> macrophages (Fig. 2A and C).


Despite the presence of a minor TA-MAC population in *CCR2* knockout mice, we found no significant tumor cell phagocytosis of TA-MAC (Fig. 2B and D). In contrast, tumor cell phagocytosis by microglia was significantly enhanced upon anti-CD47 treatment (0.9% control versus 8.7% treated,  $P = 0.0019$ ) (Fig. 2B and D). These results indicate that resident microglia are independently responsive to CD47-SIRPα blockade.

**Anti-CD47 Immunotherapy Induces Microglia-Mediated Survival Benefit.** We next wanted to investigate if microglia alone can mediate efficacy against GBM xenografts upon anti-CD47 treatment. After orthotopic injection of T387 tumor cells into either NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> or NSG-*Ccr2*<sup>RFP/RFP</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice and confirmation of tumor engraftment via bioluminescence imaging we started treatment with anti-CD47 (250 μg Hu5F9-G4 three times a week) or human IgG control. We observed significant survival benefit in the *Ccr2* haploinsufficient mice when treated with anti-CD47 compared with control (Fig. 3A and C).

As expected in the *Ccr2* knockout mice we observed a delay in tumor-induced morbidity presumably due to the lack of tumor supporting macrophages (Fig. 3B) (15). Importantly, anti-CD47 treatment led to a similar survival benefit in the absence of *Ccr2*, suggesting an effector role for microglia in myeloid checkpoint inhibition even in the absence of peripheral macrophages (Fig. 3B and C). To rule out direct inhibitory effects of anti-CD47 on glioma cells, we performed an in vitro proliferation assay and found no impairment of cell growth upon anti-CD47 treatment in two different glioma lines (T387,  $P =$  n.s.; T3832,  $P =$  n.s.), whereas the same concentration of anti-CD47 led to a highly significant increase of in vitro phagocytosis of four different glioma lines when cocultured with bone marrow-derived macrophages of NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> (T387,  $P = 0.003$ ; T4121,  $P < 0.0001$ ; T3832,  $P = 0.002$ ; and T3691,  $P = 0.002$ ) (SI Appendix, Fig. S4).

We further validated our findings in a syngeneic glioma model using the mouse glioma cell line CT2A-LUC. In the absence of *Ccr2* the TAM pool of B6-*Ccr2*<sup>RFP/RFP</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice was highly dominated by microglia (+133%,  $P = 0.003$ ) (Fig. 4A and B). As observed in the immunocompromised xenograft model, no increase in microglia composition was observed upon anti-CD47 treatment (Fig. 4A and B). Similarly, even in the absence of a functioning *Ccr2* receptor, inhibiting peripheral macrophage infiltration, anti-CD47 treatment was efficacious and reduced tumor burden significantly as indicated by bioluminescence (Fig. 4C and D). These results confirm our previous findings that microglia themselves mediate important effector functions upon myeloid checkpoint blockade in an intact immune system.





**Fig. 1.** TAM composition of T387 grafted NSG-*Ccr2*<sup>RFP/wt</sup>*Cx3cr1*<sup>GFP/wt</sup> and *Ccr2*<sup>RFP/RFP</sup>*Cx3cr1*<sup>GFP/wt</sup> mice is dominated by microglia. (A) Representative FACS plots of the TAM pool in T387-EBFP2-luc grafted NSG-*Ccr2*<sup>RFP/wt</sup>*Cx3cr1*<sup>GFP/wt</sup> and NSG-*Ccr2*<sup>RFP/RFP</sup>*Cx3cr1*<sup>GFP/wt</sup> mice, gated on CD45 positive cells. (B and C) Composition of the TAM pool in T387-EBFP2-luc grafted (B) NSG-*Ccr2*<sup>RFP/wt</sup>*Cx3cr1*<sup>GFP/wt</sup> (\**P* = 0.018 and \*\**P* < 0.0001) and (C) NSG-*Ccr2*<sup>RFP/RFP</sup>*Cx3cr1*<sup>GFP/wt</sup> mice as assessed by flow cytometry analyses on RFP<sup>negative</sup>GFP<sup>bright</sup> (microglia) and GFP<sup>low</sup>RFP<sup>+</sup> (macrophages) signal gated on CD45 positive cells. \**P* = 0.036; \*\**P* = 0.030. Results are pooled from three independent experiments (NSG-*Ccr2*<sup>RFP/wt</sup>*Cx3cr1*<sup>GFP/wt</sup> control group *n* = 11, anti-CD47 group *n* = 10). Mean ± SEM.

### In Vivo Visualization of Microglial Phagocytosis upon Anti-CD47 Treatment.

To have a better understanding of the effect of anti-CD47 treatment on the morphology and real-time kinetics of microglia response, we performed intracranial in vivo imaging of NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice grafted with the tumor cell line T387-EBFP2<sup>+</sup>-Luc. In accordance with our flow cytometry results, we observed a remarkable recruitment of macrophages upon anti-CD47 treatment (+68%, *P* = 0.018) (Fig. 1B and Movies S1 and S2). Still, TA-MG clearly outweighed TA-MAC in numbers (+117%, *P* < 0.0001) (Fig. 1A and B). Strikingly, we could capture a high proportion of microglia phagocytizing living tumor cells in real time upon anti-CD47 treatment (Fig. 5A and B and Movies S3 and S4). On the other hand, in the control situation, single tumor cells were only surveilled by microglial processes, but we were unable to visualize phagocytosis (Movie S5). To examine the morphological changes associated with anti-CD47 treatment, we compared TA-MG from mice treated with anti-CD47 or control and quantified microglial process movement using filament tracking algorithms. Interestingly, the number of microglial processes (+39.9%, *P* = 0.04) and straightness significantly increased (+241.0%, *P* = 0.005) upon anti-CD47 treatment (Fig. 5C and Movie S6 and S7), whereas the mean speed of the process movement was significantly decreased in the treated condition. This suggests a more active and directed filament movement as well as a prolonged interaction time with tumor cells.


### Distinct Transcriptional Profile of Microglia Versus Macrophages in Response to Anti-CD47 Immunotherapy.

Given their differential lineage origins, we investigated whether the functional and morphological changes of TA-MG and TA-MAC upon anti-CD47 treatment

were also associated with distinctive gene expression patterns. For this study, TA-MG (GFP<sup>high</sup>RFP<sup>negative</sup>) and TA-MAC (GFP<sup>low</sup>RFP<sup>high</sup>) from T387-EBFP2-Luc grafted NSG-*Ccr2*<sup>RFP/wt</sup>-*Cx3cr1*<sup>GFP/wt</sup> mice were sorted and processed for RNA sequencing after 3 wk of either anti-CD47 or control treatment (Fig. 6A).

Consistent with a previous study, compared with TA-MG, we found TA-MAC to express higher levels of genes associated with the alternative complement system (*Cfb*, *Cfp*), antigen-presenting functions (*Cd40*, *Cd80*), immune receptors and signaling (*Thr8*, *Jak2*), and chemotaxis (*Ccl17*, *Ccl22*) (Fig. 6E) (SI Appendix, Fig. S2D). We submitted the differentially expressed genes (*q* value < 0.05) between TA-MG and TA-MAC to Ingenuity Pathway Analysis (IPA) for functional analysis. Interestingly, functions including “inflammatory response” (*z* score = 4.3, *q* value =  $1.75 \times 10^{-7}$ ), “cell movement of myeloid cells” (*z* score = 2.8, *q* value =  $1.2 \times 10^{-6}$ ), “activation of antigen-presenting cells” (*z* score = 2.6, *q* =  $9.34 \times 10^{-5}$ ), and “chemotaxis of lymphocytes” (*z* score = 2.9, *q* value =  $1.48 \times 10^{-6}$ ) were significantly more enriched in TA-MAC than in TA-MG (SI Appendix, Fig. S2C).

Upon anti-CD47 treatment we found 63 genes to be differentially expressed by TA-MG and 89 genes by TA-MAC (Fig. 6B). Intriguingly, only eight genes were differentially expressed by both TA-MG and TA-MAC (Fig. 6B). This indicates that CD47 blockade leads to a distinct response pattern between TA-MG and TA-MAC. TA-MAC showed a significant up-regulation (*q* value < 0.1, fold change > 2) of immune receptors, chemokines (*Il1m*, *Cxcl10*, *Trl2*), complement factors (*C3*, *Cfb*), reactive oxygen species (*Cybb*, *Sod2*), M1 markers (*Fpr2*, *Irg1*), and the down-regulation of the M2 marker *Mrc1*, suggesting a notable



**Fig. 2.** Anti-CD47 treatment enhances microglial tumor phagocytosis independent of macrophage recruitment. (A and B) Representative FACS plots of dissociated tumors from EBFP2<sup>+</sup>T387-grafted (A) NSG-Ccr2<sup>RFP/wt</sup>Cx3cr1<sup>GFP/wt</sup> and (B) NSG-Ccr2<sup>RFP/RFP</sup>Cx3cr1<sup>GFP/wt</sup> mice treated with anti-CD47 or control until they reached morbidity. Microglia were defined as GFP<sup>high</sup>RFP<sup>negative</sup> and macrophages as RFP<sup>high</sup>GFP<sup>low</sup>. Anti-CD47 led to a significant increase of the double positive EBFP2<sup>+</sup>GFP<sup>+</sup> microglial and EBFP2<sup>+</sup>RFP<sup>+</sup> macrophage population in the Ccr2<sup>RFP/wt</sup> mouse model. In the Ccr2<sup>RFP/RFP</sup> model anti-CD47 treatment led to a significant increase of the EBFP2<sup>+</sup>GFP<sup>+</sup> microglial population only. (C and D) Statistical analysis of the percentage of EBFP2<sup>+</sup>GFP<sup>+</sup> microglia and EBFP2<sup>+</sup>RFP<sup>+</sup> macrophages ± anti-CD47 treatment in (C) NSG-Ccr2<sup>RFP/wt</sup>Cx3cr1<sup>GFP/wt</sup> and (D) NSG-Ccr2<sup>RFP/RFP</sup>Cx3cr1<sup>GFP/wt</sup> mice after 3 wk of treatment. \*\*\**P* = 0.0003; \*\*\*\**P* < 0.0001; \*\**P* = 0.0019; Welch's *t* test. Results are pooled from three independent experiments. (NSG-Ccr2<sup>RFP/wt</sup>Cx3cr1<sup>GFP/wt</sup> control group *n* = 12, anti-CD47 group *n* = 17) (NSG-Ccr2<sup>RFP/RFP</sup>Cx3cr1<sup>GFP/wt</sup> control group *n* = 7, anti-CD47 group *n* = 7). Mean ± SEM. ns, not significant.


proinflammatory response (Fig. 6C). TA-MG on the other hand down-regulated immune receptor-associated genes (*Hmx1*, *Il4ra*, *Ccl7*) and showed an increased expression level of anti-inflammatory genes (*Dab2*, *Mmp12*), suggesting a less inflammatory reaction (Fig. 6D). Intriguingly, genes associated with the phagocytic machinery (*Axl*) were only up-regulated in TA-MG (Fig. 6D).

### Discussion

TAMs are a major immune component of many types of cancer and can account for up to 50% of cells within the brain tumor microenvironment. Monocyte-derived macrophages are recruited by release of cytokines and chemokines due to tissue perturbation (5). While brain resident microglia are critical regulators of tissue homeostasis, their role in immune surveillance of glioma cells remains poorly understood. The evasion of programmed cell death and subsequent programmed cell removal is one of several key early events that need to be overcome in the progression from normal cellular homeostasis to malignant transformation (16). Brain cancer cells employ multiple strategies to evade innate and adaptive immunity. While we have previously shown that blocking the myeloid

checkpoint CD47-SIRPα axis is efficacious against multiple adult and pediatric brain tumors, the specific role of microglia in anti-CD47 treatment remains unclear (9, 10, 17, 18).

To delineate the GBM TAM pool we utilized a model with genetically color-coded macrophages (Ccr2<sup>RFP</sup>) and microglia (Cx3cr1<sup>GFP</sup>), which allowed us to distinguish resident microglia from infiltrating, blood-derived macrophages. The TAM composition of GBM was dominated by microglia in all tumor models. Investigating the effect of the myeloid checkpoint inhibitor anti-CD47 we found that macrophages and microglia respond by phagocytizing tumor cells. Even in the absence of infiltrating macrophages (Ccr2<sup>RFP/RFP</sup>), microglia continue to phagocytize tumor cells resulting in a significant survival benefit. RNA-seq analysis showed the enrichment of microglia-specific markers such as *Tmem119*, *Sall1*, and *Pros1* as well as macrophage-specific markers such as *Iga4* and *Iig1* validating the differentiation between TA-MG and TA-MAC in our model (12, 19, 20). Importantly, the transcriptional profile of TA-MG was characterized by a less inflammatory response to anti-CD47 treatment making the reeducation of microglia a clinically attractive target.



**Fig. 3.** Anti-CD47 treatment leads to significant survival benefit in T387 grafted mice even in absence of phagocytizing macrophages. (A and B) Kaplan-Meier curves of (A) NSG-*Ccr2*<sup>RFP/wt</sup>*Cx3cr1*<sup>GFP/wt</sup> (\**P* = 0.01) and (B) *Ccr2*<sup>RFP/RFP</sup>*Cx3cr1*<sup>GFP/wt</sup> mice (\**P* = 0.049) grafted with T387-EBFP2-luc treated with anti-CD47 (H5F9-G4) or human IgG control; purple, anti-CD47 treated; blue, control (human IgG). Arrows indicate beginning of treatment on day 7 after tumor injections. (C) Images of luminescence measurements detected with an IVIS spectrum instrument on day 30 after tumor injections. Minimum and maximum values were adjusted to the same level for the NSG-*Ccr2*<sup>RFP/wt</sup>*Cx3cr1*<sup>GFP/wt</sup> and *Ccr2*<sup>RFP/RFP</sup>*Cx3cr1*<sup>GFP/wt</sup> model. Representative survival experiment is shown. (NSG-*Ccr2*<sup>RFP/wt</sup>*Cx3cr1*<sup>GFP/wt</sup> control group *n* = 5, anti-CD47 group *n* = 5) (*Ccr2*<sup>RFP/RFP</sup>*Cx3cr1*<sup>GFP/wt</sup> control group *n* = 7, anti-CD47 group *n* = 6). Mean ± SEM.

Most therapies targeting the tumor microenvironment focus on the depletion of the TAM pool to suppress their protumorigenic effect. However, reeducating TAMs has the additional benefit of an active targeting of tumor cells (21). This is of particular interest since TAMs are genetically stable and more resistant to treatment-associated mutations (22). TAM reeducation with anti-CD47 is especially promising as SIRP $\alpha$ , the receptor of CD47, is exclusively expressed on myeloid cells. CD47 is ubiquitously overexpressed on malignant human tumors, including malignant pediatric brain tumors and GBM (9, 10). The clinical relevance of immune escape by CD47 up-regulation on tumor cells is also reflected by correlation studies: high levels of CD47 expression are associated with a decreased probability of overall survival in GBM (9).

Treatment-associated neurotoxicity is a common problem of immunotherapy. Cytokine release causes inflammation of the brain which is associated with serious complications like cerebral edema and increase of intracranial pressure (23, 24). In this context it might be especially important that we find microglia showing a less inflammatory response to anti-CD47, although the phagocytosis rate of TA-MG is even higher than that of TA-MAC. This makes microglia an attractive target for clinical applications.

Triggering of phagocytosis is a balancing act determined by pro- and antiphagocytic signals. The blockade of CD47 is only effective in combination with the presence of prophagocytic signals such as calreticulin and phosphatidylserine. A limitation of our study is the modest efficacy of anti-CD47 treatment alone. Future studies combining anti-CD47 therapy with cytotoxic therapies such as chemotherapy and low-dose radiation, which are known to increase surface expression of prophagocytic signals, need to be conducted to assess the full potential of CD47 blockade (25). Other studies demonstrated that anti-CD47 therapy elicits a


type I IFN-mediated priming of the adaptive immune system (26). Thus, combinational therapies with checkpoint inhibitors and other regulators of the adaptive immune system might also be promising. This is also supported by a recent report of a phase Ib/II study with non-Hodgkin lymphoma patients showing encouraging clinical responses for the combination therapy of anti-CD47 and rituximab (27).

To date only few options exist to selectively deplete macrophages. Pharmacological depletion of brain tumor-associated macrophages with either anti-CSF1R antibodies or liposomal clodronate is effective but unselective, since it also depletes microglia (28, 29). Homozygous knockout of CCR2 prevents selectively the entry of monocytes into the CNS while maintaining microglial function. The absence of T, B, and NK cells in NSG mice enables a more precise analysis of myeloid cell function without confounding influence by the adaptive immune system. We further ruled out direct inhibitory effects of anti-CD47 as another potential underlying antitumor effect on glioma cells as suggested by a previous study by Li et al. (30) and found no impairment of tumor cell proliferation by anti-CD47 treatment. Our analysis of myeloid infiltration demonstrated that a small number of monocytes is able to penetrate the blood brain barrier (BBB) independent of *Ccr2*. This might be due to the disrupted BBB that is often encountered in malignant brain tumors (31). However, these infiltrating macrophages were not capable of phagocytosis so that we could demonstrate a macrophage-independent antitumor effect by microglia. This effect was maintained in our syngeneic glioma model indicating that interactions with the adaptive immune system do not impede the reeducation of microglia. The antibodies used in each of the cases have significantly different binding affinities. The anti-HuCD47 mAb has a 100-fold higher binding affinity compared with the anti-msCD47 mAb hence showing different levels









**Fig. 6.** RNA-seq analysis reveals distinct transcriptional profiles of tumor-associated macrophages and microglia. (A) Experimental scheme for the RNA-seq experiment. (B) Venn diagram of significantly differentially expressed genes ( $q$  value  $< 0.1$ ) in TA-MAC (red) (control group  $n = 3$ , anti-CD47 group  $n = 3$ ) and TA-MG (green) (control group  $n = 3$ , anti-CD47 group  $n = 3$ ) of mice treated with anti-CD47 or control. (C and D) Volcano plots of differentially expressed genes between (C) TA-MAC control versus treated and (D) TA-MG control versus treated. The  $P$  values are Benjamini-Hochberg corrected. (E) Heatmap depicting row  $z$  scores of  $\log_2$ -transformed gene expression of TA-MAC control (light red), TA-MAC treated (red), TA-MG control (light green), and TA-MG treated (green).

acids, sodium pyruvate, HEPES, glutamine and antibiotic-antimycotic (Corning). Following mechanical trituration, cells were filtered through 70- $\mu$ m and 40- $\mu$ m filters and subjected to a 0.9 M sucrose gradient centrifugation to dispose of dead cells and myelin. Upon ACK lysis for removal of erythrocytes (Gibco Life Technologies) cells were resuspended in FACS buffer containing HBSS, 1% BSA, nonessential amino acids, sodium pyruvate, HEPES, EDTA, glutamine, and antibiotic-antimycotic (Corning) and stained with the following antibodies: Antibodies used for flow cytometry analysis are shown in *SI Appendix, Table S3*. DAPI stain (Invitrogen) or Sytox Red (APC, Invitrogen) were used to exclude dead cells.

Flow cytometric analysis and cell sorting were performed on the BD FACS Aria II (Becton Dickinson). The flow-cytometry gating strategy for sorting of microglia and macrophages is depicted in *SI Appendix, Fig. S5*.

**Cranial Window Surgery.** At 5 d before the implantation of the windows, orthotopic tumors ( $1 \times 10^5$  T387-EBFP2-Luc cells) were transplanted at a depth of 2 mm below the dura as described above. Eight- to 12-wk-old NSG-Ccr2<sup>RFP/wt</sup>-Cx3cr1<sup>GFP/wt</sup> mice were anesthetized via intramuscular injection with ketamine/xylazine (87.5 mg/kg ketamine, 12.5 mg/kg xylazine). The animals' body temperatures were maintained at 36.5–37.5 °C using a heating



pad connected to a controller (DC temperature controller, FHC), and their eyes were covered with eye protecting gel (Solcorin; Solco Basie, Ltd). The scalp was shaved and the surgical field scrubbed and thoroughly disinfected with ethanol and betadine. Thereafter, the frontobiparietal scalp and periosteum was excised and surface of the cranium irrigated with hydrogen peroxide. A right-sided or bilateral frontoparietal bone flap was drilled and carefully detached from the underlying dura mater followed by extensive irrigation with 0.9% saline. We opened and removed the dura on the right hemisphere with a thin 30-G needle under the microscope under strict avoidance of superior sagittal sinus or other venous bleeding. We irrigated again with saline and covered the tumor-centered craniectomy with a sterile, thick cover glass (hemocytometer coverglass, VWR) that was previously size adjusted using a diamond cutter. The borders of the coverglass were glued to the bone using cyanoacrylate glue (Loctite). For recovery, mice were s.c. injected with 0.1 mg/kg buprenorphine and fed with antibiotic-enriched UNIPRIM food (Neogen). Subsequently, mice were treated with 250  $\mu$ g of anti-CD47 antibody (H5F9-G4) or human IgG control three times a week (Monday/Wednesday/Friday) beginning at day 7 after tumor injections. Tumor engraftment was verified by bioluminescence imaging before treatment began.

**Two-Photon In Vivo Microscopy and Confocal In Vivo Microscopy.** Intravital two-photon images were acquired with a Prairie Ultima IV two-photon in vivo microscope (Bruker) equipped with two Ti:Sapphire lasers (MaiTai HP, Spectra Physics) tuned to 810 nm (for excitation of EBFP2<sup>+</sup> tumor cells) and 920 nm (for excitation of GFP<sup>+</sup> microglia and RFP<sup>+</sup> macrophages), respectively, and focused through an Olympus XLUM Plan Fluor 20 $\times$  water immersion lens (numeric aperture of 0.95). Before imaging, mice were anesthetized with isoflurane and the head was fixed in a stereotaxic frame (Kopf Instruments). Anesthesia was maintained at 1% isoflurane through a nose cone, and body temperature was kept stable via a temperature-controlled heating pad. Images of 598  $\times$  598  $\mu$ m<sup>2</sup> areas of in vivo tumors were acquired at 1,024  $\times$  1,024 pixel resolution (0.584  $\mu$ m per pixel). Volume images were acquired over a 100- to 200- $\mu$ m Z range in 1- $\mu$ m steps. Time-lapse datasets were acquired either in single planes over time periods up to 90 min, or in combined time + Z series over a 598  $\times$  598  $\times$  7  $\mu$ m<sup>3</sup> volume (X  $\times$  Y  $\times$  Z). Movies were processed in ImageJ software; for 3D reconstructions, data were imported into Imaris software (BitPlane) for surface rendering. Microglial process movement over time was quantified using the filament tracking tool of Imaris. Quantitative parameters were extracted and utilized for univariate and multivariate logistic regression, with anti-CD47 treatment serving as a binomial response variable.

Confocal in vivo microscopy was performed using an Olympus IV100 intravital laser scanning microscope. To visualize blood vessels, AngioSense 680 (PerkinElmer) dye was injected into the tail vein. Data were analyzed with ImageJ and Imaris.

**RNA Extraction from Sorted Cells, cDNA, and Library Preparation.** After grafting *NSG-Ccr2<sup>RFP/wt</sup>Cx3cr1<sup>GFP/wt</sup>* mice with the T387-EBFP2-luc cell line and treating the mice for 3 wk with i.p. injections of 250  $\mu$ g of anti-CD47 (H5F9-G4) or human IgG control three times a week (Monday/Wednesday/Friday), we sorted between 2,000 and 30,000 tumor-associated microglia and macrophages directly into TRIzol LS (Invitrogen). RNA was extracted via a combined TRIzol and column cleanup protocol for low cell amounts. Additionally, the RNA was DNase treated. Subsequently, the integrity of extracted RNA was assayed by on-chip electrophoresis (Agilent Bioanalyzer) and only samples with a high RNA integrity (RIN) value >7 were used for RNA-seq. Purified total RNA was reverse transcribed into cDNA using the Ovation RNA-seq System V2 (NuGEN) and cDNA was sheared using the Covaris S2 system (duty cycle 10%, intensity 5, cycle/burst 100, total time 5 min). Sheared cDNA was cleaned up using Agencourt AMPure XP beads (Beckman Coulter) and ligated to adaptors (Illumina) Sequencing libraries were constructed using the NEBNext Ultra DNA Library Prep Kit (New England Biolabs) using barcoded adaptors to enable multiplexing of libraries on the same sequencing lane. For each RNA-seq library, the effectiveness of adaptor ligation and effective library concentration was determined by Bioanalyzer before loading them in multiplexed fashion onto an Illumina NextSeq500 (Stanford Functional Genomics Facility) to obtain 150 bp paired-end reads.

**RNA-Seq Analysis.** First, raw reads were trimmed using Skewer (v0.2.2) to remove the adaptors. We then followed the ENCODE long RNA-seq pipeline for expression quantification (<https://www.encodeproject.org/rna-seq/long-rnas/>) (The ENCODE Project Consortium, 2012). Specifically, reads were aligned to the mm10 genome with STAR (v2.5.3) using two-pass mapping (36). Genome indices were created with Samtools (v1.4.1) (37). For expression level quantification and differential expression analysis, we used the Cufflink package (v2.2.1) and applied the Cuffdiff and Cuffquant programs to the aligned reads (37). For functional analysis with IPA (v01-10) we provided fragments per kilobase million (FPKM), log<sub>2</sub>(fold change), *P* values, and false discovery rates from Cufflink.

**Proliferation Assay.** For real-time analysis, IncuCyte Zoom System (Essen BioScience) was utilized. T387 or T3832-RFP cells were seeded into 96-well plates and treated with a final concentration of 10  $\mu$ g/mL anti-CD47 or PBS. The culture plate was incubated in an IncuCyte Zoom System in a cell culture incubator. Cell images were captured in four fields per well every 3 h. Total red object integrated intensity (GCU  $\times$   $\mu$ m<sup>2</sup>/image) was determined using IncuCyte Zoom software (Essen BioScience).

**In Vitro Phagocytosis Assay.** Mouse macrophages were obtained from 7- to 10-wk-old *NSG-Ccr2<sup>RFP/wt</sup>* mouse bone marrow. Briefly, mice were killed in a CO<sub>2</sub> chamber and femora and tibiae were isolated. The bones were kept in ice-cold PBS and sterilized in 70% ethanol. By flushing them with mouse macrophage medium (RPMI with 10% FBS, 1 $\times$  penicillin/streptomycin, 200 mM glutamine, and 25 mM Hepes, all from Corning, Inc.), bone marrow cells were gathered and plated at 1  $\times$  10<sup>6</sup>/mL in 100  $\times$  25 mm Petri dishes in mouse macrophage medium containing 10 nM m-CSF. The medium was changed after 3 d and cells were harvested for experiments on days 7–10.

Dissociated EBFP2<sup>+</sup> tumor cells were incubated with bone marrow-derived macrophages in serum-free Iscove's modified Dulbecco minimum essential medium with or without prior addition of 10  $\mu$ g/mL anti-CD47 monoclonal antibody (H5F9-G4, IgG4) at 37  $^{\circ}$ C for 2 h in ultra-low attachment round-bottom 96-well plates. The tumor cell to macrophage or microglia ratio was 2:1. Cells were analyzed with a BD LSR Fortessa (Becton Dickinson) using a high throughput sampler. Gates were placed according to unstained and fluorescence-minus-one (FMO) controls. Technical duplicates of each experimental condition were obtained.

**Statistical Analysis.** All statistical analyses were performed using GraphPad Prism 7 software. Results were expressed as mean  $\pm$  SEM. Welch's *t* test was used for group comparisons (two tailed). Survival analysis was performed using a log-rank test. *P* < 0.05 was considered significant if not stated otherwise.

**ACKNOWLEDGMENTS.** We thank Dr. Jeremy Rich (Cleveland Clinic) for providing glioblastoma cell line T387; Dr. Thomas Seyfried (Department of Biology, Boston College) for the CT-2A mouse glioma cell line; Patricia Lovelace and Jennifer Ho (Stem Cell FACS Core facility, Stanford University) for technical support during flow cytometry experiments; Tim Doyle [Stanford Center for Innovation in In Vivo Imaging (SCI3)] for technical support during bioluminescence imaging; members of the I.L.W. and S.H.C. laboratories for their help during various experiments; and Michael Alvarez and the Stanford University veterinary services staff for their help with animal husbandry. Funding was provided by Stanford Neuroscience Microscopy Service, supported by NIH NS069375; Swiss National Science Foundation Grant P-155336 (to G.H.); the Novartis Foundation for Medical-Biological Research (G.H.); Department of Neurosurgery, University Hospital Basel (G.H.); German Cancer Aid (Deutsche Krebshilfe); German Academic Scholarship Foundation (C.M.G.); a Stanford Medical Scholars Translational Science Research Grant (to M.K.S.); the Price Family Charitable Fund; the Center for Children's Brain Tumors (Stanford University) (S.G., S.S.M., and S.H.C.); Ty Louis Campbell Foundation St. Baldrick's Scholar; Kathryn S. R. Lowry Endowed Chair (S.H.C.); the American Brain Tumor Foundation (S.H.C. and T.D.A.); a Siebel Scholars Award from the Siebel Stem Cell Institute (to S.S.M.); Emerson Collective Cancer Research Fund (S.S.M., G.G., S.H.C.); a Pew Latin American Fellowship (to S.A.K.); the Virginia and D. K. Ludwig Fund for Cancer Research (I.L.W. and S.H.C.); Tashia and John Morgridge Endowed Pediatric Faculty Scholar and Fellowships Awards (to S.H.C.); and gifts from George Landegger, Rider and Victoria McDowell, Charles Comey and Judith Huang, and Colin and Jenna Fisher (to S.H.C.).

- Darefsky AS, King JT, Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: A population-based analysis of surveillance, epidemiology, and end results registries. *Cancer* 118:2163–2172.
- Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. *Nat Med* 19:1423–1437.
- Shi C, Pamer EG (2011) Monocyte recruitment during infection and inflammation. *Nat Rev Immunol* 11:762–774.

- Ginhoux F, et al. (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 330:841–845.
- Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. *Nat Neurosci* 19:20–27.
- Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. *Nat Neurosci* 14:1142–1149.

7. Shemer A, Jung S (2015) Differential roles of resident microglia and infiltrating monocytes in murine CNS autoimmunity. *Semin Immunopathol* 37:613–623.
8. Jaiswal S, et al. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell* 138:271–285.
9. Willingham SB, et al. (2012) The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci USA* 109:6662–6667.
10. Gholamin S, et al. (2017) Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. *Sci Transl Med* 9:eaaaf2968.
11. Mizutani M, et al. (2012) The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. *J Immunol* 188:29–36.
12. Bowman RL, et al. (2016) Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. *Cell Rep* 17:2445–2459.
13. Saederup N, et al. (2010) Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. *PLoS One* 5:e13693.
14. Liu J, et al. (2015) Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. *PLoS One* 10:e0137345.
15. Vakilian A, Khorramdelazad H, Heidari P, Sheikh Rezaei Z, Hassanshahi G (2017) CCL2/CCR2 signaling pathway in glioblastoma multiforme. *Neurochem Int* 103:1–7.
16. Chao MP, Majeti R, Weissman IL (2011) Programmed cell removal: A new obstacle in the road to developing cancer. *Nat Rev Cancer* 12:58–67.
17. Zhang M, et al. (2016) Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. *PLoS One* 11:e0153550.
18. Esparza R, Azad TD, Feroze AH, Mitra SS, Cheshier SH (2015) Glioblastoma stem cells and stem cell-targeting immunotherapies. *J Neurooncol* 123:449–457.
19. Bennett ML, et al. (2016) New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci USA* 113:E1738–E1746.
20. Buttgerit A, et al. (2016) Sall1 is a transcriptional regulator defining microglia identity and function. *Nat Immunol* 17:1397–1406.
21. Quail DF, Joyce JA (2017) The microenvironmental landscape of brain tumors. *Cancer Cell* 31:326–341.
22. Quail DF, et al. (2016) The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. *Science* 352:aad3018.
23. Gust J, et al. (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov* 7:1404–1419.
24. Spain L, et al. (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. *Ann Oncol* 28:377–385.
25. Obeid M, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. *Nat Med* 13:54–61.
26. Liu X, et al. (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. *Nat Med* 21:1209–1215.
27. Advani RH, et al. (2018) Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. *J Clin Oncol* 36(15\_suppl):7504.
28. Elmore MR, et al. (2014) Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. *Neuron* 82:380–397.
29. Fulci G, et al. (2007) Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. *Cancer Res* 67:9398–9406.
30. Li F, et al. (2017) Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. *Oncoimmunology* 7:e1391973.
31. Davies DC (2002) Blood-brain barrier breakdown in septic encephalopathy and brain tumours. *J Anat* 200:639–646.
32. Jung S, et al. (2000) Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol Cell Biol* 20:4106–4114.
33. Shultz LD, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hematopoietic stem cells. *J Immunol* 174:6477–6489.
34. Maruyama C, et al. (2002) Genotyping the mouse severe combined immunodeficiency mutation using the polymerase chain reaction with confronting two-pair primers (PCR-CTPP). *Exp Anim* 51:391–393.
35. Takenaka K, et al. (2007) Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. *Nat Immunol* 8:1313–1323.
36. Dobin A, et al. (2013) STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* 29:15–21.
37. Trapnell C, et al. (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 7:562–578.